DUBLIN--(BUSINESS WIRE)--The "Global Medical Marijuana Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.
The global medical marijuana market was valued at US$ 13,908.7 million in 2017, and is expected to reach US$ 57,582.5 million by 2026, expanding at a CAGR of 17.1% from 2018 to 2026.
Cancer is currently dominating the applications segment on account of large patient pool suffering with chronic pain and nausea during chemotherapy. Marijuana have been found beneficial in treating patients with neurological disorders such as epilepsy, seizures etc., due to its sedative effects. Chronic pain will gain momentum due to increasing number of patients suffering with musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis and other autoimmune diseases such as psoriasis and multiple sclerosis.
In the present scenario hospital pharmacies are dominating the point of sale segment on account of key parameters such as availability of medical marijuana at low cost and strict monitoring of cancer patients availing marijuana for treating chronic pain. Dispensaries will register good growth during the forecast period due to increasing number of patients suffering with anorexia and nausea and government permit to dispense marijuana on regular basis to patients suffering with chronic pain.
North America is the global leader in medical marijuana market owing to the rising prevalence of cancer and proactive policies implemented by USFDA legalizing the production and sale of marijuana for treating chronic pain. Germany has drafted regulatory guidelines for the use of marijuana for medicinal purpose which also serves as a gold standard for other European Union countries. Rest of the World serves as a lucrative market as it is the largest producer of marijuana in the world and regulatory agencies are taking proactive steps to legalize the production and sale of marijuana for therapeutic use.
The key players actively engaged in the production and sale of marijuana are AbbVie, Inc., CannaGrow Holdings, Inc., Canopy Growth Corporation, Inc., GW Pharmaceuticals, Plc. Insys Therapeutics, Inc., Novartis AG, Lexaria Corporation, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and United Cannabis Corporation.
Key Market Movements
- Rising prevalence of cancer and patients suffering with chronic pain
- Increased research funding for determining the therapeutic efficacy of marijuana for treating anorexia and nausea
- Supportive regulatory environment for the production and sale of marijuana for medicinal purposes
Topics Covered:
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Scope
1.3. Research Methodology
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global Medical Marijuana Market Portraiture
2.2. Global Medical Marijuana Market, by Application, 2017 (US$ Mn)
2.3. Global Medical Marijuana Market, by Point of Sale, 2017 (US$ Mn)
2.4. Global Medical Marijuana Market, by Geography, 2017 (US$ Mn)
Chapter 3. Medical Marijuana Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Medical Marijuana Market, by Key Players, 2017
Chapter 4. Global Medical Marijuana Market, by Application
4.1. Overview
4.2. Chronic Pain
4.3. Neurological Disorders
4.4. Cancer
4.5. Others (Anorexia, Nausea etc.)
Chapter 5. Global Medical Marijuana Market, by Point of Sale
5.1. Overview
5.2. Hospital Pharmacy
5.3. Dispensaries
Chapter 6. Global Medical Marijuana Market, by Geography
6.1. Overview
6.2. North America Medical Marijuana Market Analysis, 2016 - 2026
6.3. Europe Medical Marijuana Market Analysis, 2016 - 2026
6.4. Latin America Medical Marijuana Market Analysis, 2016 - 2026
6.5. Rest of World Medical Marijuana Market Analysis, 2016 - 2026
Chapter 7. Company Profiles
7.1. AbbVie Inc.
7.2. CannaGrow Holdings Inc.
7.3. Canopy Growth Corporation Inc.
7.4. GW Pharmaceuticals PLC
7.5. Insys Therapeutics Inc.
7.6. Novartis AG
7.7. Lexaria Corporation
7.8. Pfizer Inc.
7.9. Teva Pharmaceutical Industries Ltd.
7.10. United Cannabis Corporation
For more information about this report visit https://www.researchandmarkets.com/research/53tr9t/global_medical?w=4
